Company intelligence / Profile preview

BioLoomics

Boulder, Colorado, United Statesbioloomics.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

BioLoomics has developed a proprietary directed evolution platform to create next-generation ADCs and target-degrading antibodies. The company’s approach enables rapid design and testing of antibody variants with improved internalization and payload delivery. As of early 2025, all programs are preclinical; no clinical results have been reported yet.

Therapeutic areas: Oncology
Modalities: Antibody Drug Conjugates (ADCs)Antibody-peptide chimerasTarget degrading antibodies
Industry: Biotech

Partnerships

Strategic partnerships planned or forming with large pharma companies; specifics undisclosed as of May 2025.

Beyond the preview

Go deeper on BioLoomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioLoomics.

Explore the full profile